Fig. 7: Comparison of lestaurtinib and ruxolitnib effects on ovarian cancer inhibition and regulation of JAK/STAT signaling. | npj Precision Oncology

Fig. 7: Comparison of lestaurtinib and ruxolitnib effects on ovarian cancer inhibition and regulation of JAK/STAT signaling.

From: Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Fig. 7

a Dose response curves (twofold dilution starting at 200 µM) and IC50 concentrations for ruxolitinib in a panel of therapy-sensitive and -resistant ovarian cancer cell lines following 5–10 days of treatment. N = 8. b Viability of PDX models following 3 days of ruxolitinib treatment ex vivo as assessed via 3D CellTiter-Glo. N = 3–6. c Expression of indicated STAT1 and STAT3 regulated genes following 24 h of treatment with DMSO, 250 nM lestaurtinib or 250 nM ruxolitinib. d Western blots depicting the levels of STAT1 and STAT3 phosphorylation following treatment with DMSO or indicated concentrations of lestaurtinib and ruxolitinib for 30 min. Actin served as the loading control. Abbreviations: Cis Res cisplatin resistant, OlapR olaparib-resistant, Lest lestaurtinib, Ruxo ruxolitinib. Graphs depict mean ± standard error. ANOVA p-values: *<0.0332,**<0.0021,***<0.0002,****<0.0001.

Back to article page